
    
      This is a multicenter, randomized, double-blind placebo controlled study of efficacy and
      safety of characterized peanut OIT in peanut allergic individuals. All eligible subjects will
      receive an escalating dose of CPNA or placebo. Approximately 50 subjects will be randomized
      1:1 to peanut OIT or placebo.
    
  